World Fusion Launches Global Target Discovery Services and Powerful AI Literature Platform "LiBLA"

Tokyo, Japan — [Month Day, 2025] — World Fusion Co., Ltd., a leading bioinformatics company, today announced the global launch of two innovative offerings aimed at accelerating early-stage drug discovery and translational research: a new target discovery contract research service, and LiBLA (Literature Lookup Assistant) — an advanced, AI-powered PubMed analysis platform.

Designed for pharmaceutical, biotech, and academic researchers, these solutions bring powerful data integration, AI analytics, and literature intelligence to the forefront of biomedical R&D.

🔬 Smarter Discovery Starts with Smarter Data

World Fusion’s contract research services support early-phase drug discovery, biomarker identification, and precision medicine development by combining curated biomedical databases with proprietary analytics pipelines. The service includes:

• Target and Biomarker Discovery: Integrating over 60 public and proprietary databases
  
  
• In Silico Phenotype Prediction: AI-based inference from expression and pathway data
  
  
• Microbiome & Metagenomic Analysis: For disease, drug response, and environmental studies
  
  

These services are designed for pharma, biotech startups, and academic labs looking to accelerate discovery timelines without building in-house analytics infrastructure.

🧠 Introducing LiBLA: AI-Powered Literature Analysis Platform

Also debuting is LiBLA (Literature Lookup Assistant) — an AI platform that helps researchers efficiently navigate the overwhelming volume of scientific publications.

What sets LiBLA apart is its seven-category biomedical ontology system combined with an optimized text mining engine. Together, they deliver unmatched precision and relevance in literature search, going far beyond traditional keyword-based tools.

LiBLA allows users to:

• Search semantically across millions of PubMed abstracts
  
  
• Prioritize articles using context-aware feedback loops
  
  
• Export structured knowledge for further analysis or reporting
  
  

LiBLA also introduces powerful user-driven discovery tools:

Users can create themed folders and register papers of interest.
LiBLA then automatically extracts characteristic terms with importance scores (TF-IDF) and applies a proprietary document similarity algorithm based on Euclidean distance to recommend new, relevant publications.
This greatly reduces the challenge of formulating complex search queries, minimizes the risk of missing key studies, and enables the discovery of unexpected but highly relevant literature.

“LiBLA is built to make PubMed work for scientists — not the other way around,” said Kozo Kawahara, CEO of World Fusion. “It uncovers hidden insights and connections that researchers might otherwise miss.”

The platform is now available globally, with the U.S. market prioritized for early access and partnerships.

🤝 Collaboration Opportunities Open

World Fusion welcomes partnerships with pharmaceutical companies, CROs, research institutions, and digital health companies seeking to streamline discovery, optimize literature workflows, or enrich internal data assets.

For media inquiries, demo requests, or collaborations, contact:
📧 support@w-fusion.com
🌐 www.w-fusion.com
🔗 LiBLA: https://www.w-fusion.com/libla

About World Fusion
Founded in Tokyo, World Fusion Co., Ltd. develops advanced bioinformatics tools and contract research solutions that empower scientists to work smarter with biomedical data. The company specializes in ontology-based analytics, data integration, and AI platforms for the life sciences.